BridgeBio Oncology Therapeutics Inc.

BBOT | NASDAQ

$4.66

-$0.11 (-2.31%)

At close: Sep 21, 2026, 4:00 PM ET

$4.58

-$0.08 (-1.72%)

After-hours: Sep 21, 2026, 7:30 PM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021
Revenue	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a
Operating Income	-145.82M	-80.86M	-64.77M	-3.52K	-43.36K
Interest Income	11.34M	8.46M	72K	n/a	n/a
Pretax Income	-134.04M	-74.28M	-64.7M	-3.52K	-43.36K
Net Income	-134.04M	-74.28M	-64.7M	-3.52K	-43.36K
Selling & General & Admin	24.62M	7.76M	8.49M	3.52K	43.36K
Research & Development	121.2M	73.11M	56.29M	n/a	n/a
Other Expenses	n/a	n/a	n/a	n/a	n/a
Operating Expenses	145.82M	80.86M	64.77M	3.52K	43.36K
Interest Expense	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	145.82M	80.86M	64.77M	3.52K	43.36K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	31.14M	16.64M	20.49M	20.49M	20.49M
Shares Outstanding (Diluted)	31.14M	16.64M	20.49M	20.49M	20.49M
EPS (Basic)	-4.30	0.46	-3.16	n/a	0
EPS (Diluted)	-4.30	0.46	-3.16	0	0
EBITDA	-145.21M	-80.66M	-64.68M	-3.52K	-43.36K
EBIT	-145.82M	-80.86M	-64.77M	-3.52K	-43.36K
Depreciation & Amortization	610K	208K	92K	3.52K	74.33K